Neogen Corporation (NEOG) Shareholder Equity
- 2026-05-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $34.80M; Additional Paid in CapitalUSD $2.62B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-13.60M.
- 2026-02-28: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $34.80M; Additional Paid in CapitalUSD $2.61B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-12.50M.
- 2025-11-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $34.80M; Additional Paid in CapitalUSD $2.61B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-25.61M.
- 2025-08-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $34.77M; Additional Paid in CapitalUSD $2.61B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-23.48M.
Neogen Corporation Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | (m) | $34.80M | $2.62B | $-13.60M | $-544.30M | $2.09B | $2.09B | (m) | (m) |
| 2026-02-28 | (m) | $34.80M | $2.61B | $-12.50M | $-533.00M | $2.10B | $2.10B | (m) | (m) |
| 2025-11-30 | (m) | $34.80M | $2.61B | $-25.61M | $-516.01M | $2.10B | $2.10B | (m) | (m) |
| 2025-08-31 | $0.00 | $34.77M | $2.61B | $-23.48M | $-500.09M | $2.12B | $2.12B | (m) | (m) |
| 2025-05-31 | $0.00 | $34.70M | $2.60B | $-28.90M | $-536.40M | $2.07B | $2.07B | (m) | (m) |
| 2025-02-28 | $0.00 | $34.73M | $2.60B | $-47.69M | $75.77M | $2.66B | $2.66B | (m) | (m) |
| 2024-11-30 | $0.00 | $34.71M | $2.59B | $-44.74M | $86.73M | $2.67B | $2.67B | (m) | (m) |
| 2024-08-31 | $0.00 | $34.67M | $2.59B | $-31.42M | $543.01M | $3.14B | $3.14B | (m) | (m) |
| 2024-05-31 | $0.00 | $34.66M | $2.58B | $-30.02M | $555.62M | $3.14B | $3.14B | $-31.89M | (m) |
| 2024-02-29 | $0.00 | $34.66M | $2.58B | $-29.47M | $561.03M | $3.15B | $3.15B | (m) | (m) |
| 2023-11-30 | $0.00 | $34.64M | $2.57B | $-25.13M | $563.06M | $3.15B | $3.15B | (m) | (m) |
| 2023-08-31 | $0.00 | $34.61M | $2.57B | $-26.50M | $566.54M | $3.15B | $3.15B | (m) | (m) |
| 2023-05-31 | $0.00 | $34.60M | $2.57B | $-33.25M | $565.04M | $3.13B | $3.13B | $-30.29M | (m) |
| 2023-02-28 | $0.00 | $34.59M | $2.56B | $-33.22M | $559.47M | $3.13B | $3.13B | (m) | (m) |
| 2022-11-30 | $0.00 | $34.58M | $2.56B | $-40.50M | $551.28M | $3.11B | $3.11B | (m) | (m) |
| 2022-08-31 | $0.00 | $17.25M | $312.75M | $-39.33M | $593.12M | $883.80M | $883.80M | (m) | (m) |
| 2022-05-31 | $0.00 | $17.25M | $309.98M | $-27.77M | $587.91M | $887.37M | $887.37M | (m) | (m) |
| 2022-02-28 | $0.00 | $17.25M | $307.78M | $-22.44M | $572.95M | $875.54M | $875.54M | (m) | (m) |
| 2021-11-30 | $0.00 | $17.24M | $304.96M | $-24.23M | $567.51M | $865.48M | $865.48M | (m) | (m) |
| 2021-08-31 | $0.00 | $17.20M | $297.69M | $-16.20M | $556.68M | $855.36M | $855.36M | (m) | (m) |
| 2021-05-31 | $0.00 | $17.20M | $294.95M | $-11.38M | $539.60M | $840.38M | $840.38M | (m) | (m) |
| 2021-02-28 | $0.00 | $8.56M | $290.12M | $-14.84M | $523.84M | $807.68M | $807.68M | (m) | (m) |
| 2020-11-30 | $0.00 | $8.52M | $273.50M | $-15.09M | $510.47M | $777.39M | $777.39M | (m) | (m) |
| 2020-08-31 | $0.00 | $8.49M | $264.18M | $-15.71M | $494.58M | $751.55M | $751.55M | (m) | (m) |
| 2020-05-31 | $0.00 | $16.94M | $249.22M | $-19.71M | $478.72M | $725.18M | $725.18M | (m) | (m) |
| 2020-02-29 | (m) | $8.47M | $254.54M | $-13.51M | $462.38M | $711.87M | $711.87M | (m) | (m) |
| 2019-11-30 | $0.00 | $8.43M | $244.23M | $-11.92M | $450.18M | $690.92M | $690.92M | (m) | (m) |
| 2019-08-31 | $0.00 | $8.39M | $232.16M | $-14.14M | $433.90M | $660.31M | $660.31M | (m) | (m) |
| 2019-05-31 | $0.00 | $8.36M | $221.94M | $-11.64M | $419.25M | $637.90M | $637.90M | (m) | (m) |
| 2019-02-28 | $0.00 | $8.34M | $217.27M | $-9.13M | $403.43M | $619.92M | $619.92M | (m) | (m) |
| 2018-11-30 | (m) | $8.33M | $215.62M | $-12.23M | $390.36M | $602.07M | $602.07M | (m) | (m) |
| 2018-08-31 | $0.00 | $8.32M | $211.52M | $-12.52M | $374.31M | $581.63M | $581.63M | (m) | (m) |
| 2018-05-31 | $0.00 | $8.28M | $202.57M | $-9.75M | $359.07M | $560.17M | $560.17M | (m) | (m) |
| 2018-02-28 | (m) | $8.25M | $197.25M | $-5.30M | $341.46M | $541.65M | $541.93M | (m) | (m) |
| 2017-11-30 | (m) | $8.24M | $193.71M | $-6.47M | $324.87M | $520.36M | $520.64M | (m) | (m) |
| 2017-08-31 | (m) | $6.12M | $180.13M | $-7.00M | $307.77M | $487.02M | $487.25M | (m) | (m) |
| 2017-05-31 | (m) | $8.15M | $174.74M | $-7.20M | $295.93M | $471.61M | $471.76M | (m) | 12 month · $3.92M |
| 2017-02-28 | (m) | $6.10M | $169.67M | $-7.69M | $283.45M | $451.53M | $451.66M | (m) | 9 month · $3.67M |
| 2016-11-30 | (m) | $6.08M | $163.63M | $-8.13M | $273.17M | $434.74M | $434.77M | (m) | 6 month · $2.48M |
| 2016-08-31 | $0.00 | $6.03M | $155.68M | $-6.52M | $262.01M | $417.20M | $417.22M | (m) | 3 month · $728.00M |
| 2016-05-31 | $0.00 | $6.01M | $150.00M | $-3.95M | $252.13M | $404.20M | $404.16M | (m) | 12 month · $2.94M |
| 2016-02-29 | $0.00 | $6.00M | $145.29M | $-5.69M | $242.28M | $387.87M | $387.87M | (m) | (m) |
| 2015-11-30 | $0.00 | $5.99M | $141.37M | $-3.45M | $233.97M | $377.88M | $377.90M | (m) | (m) |
| 2015-08-31 | $0.00 | $5.98M | $138.23M | $-3.15M | $224.89M | $365.95M | $365.91M | (m) | (m) |
| 2015-05-31 | $0.00 | $5.94M | $131.91M | $-2.44M | $215.57M | $350.97M | $350.96M | (m) | 12 month · $2.48M |
| 2015-02-28 | $0.00 | $5.93M | $126.80M | $-2.13M | $206.19M | $336.77M | $336.71M | (m) | (m) |
| 2014-11-30 | $0.00 | $5.91M | $123.64M | $-1.49M | $198.73M | $326.80M | $326.78M | (m) | (m) |
| 2014-08-31 | (m) | $5.91M | $121.91M | $152.00K | $190.93M | $318.90M | $318.87M | (m) | (m) |
| 2014-05-31 | $0.00 | $5.88M | $118.07M | $371.00K | $182.04M | $306.36M | $306.30M | (m) | 12 month · $4.76M |
| 2014-02-28 | $0.00 | $5.86M | $110.50M | $336.00K | $174.51M | $291.20M | $291.12M | (m) | (m) |
| 2013-11-30 | $0.00 | $5.86M | $108.24M | $-160.00K | $167.93M | $281.87M | $281.81M | (m) | 6 month · $2.11M |
| 2013-08-31 | $0.00 | $3.88M | $106.24M | $-1.04M | $161.72M | $270.80M | $270.72M | (m) | 3 month · $1.58M |
| 2013-05-31 | $0.00 | $5.77M | $99.94M | $-1.37M | $153.88M | $258.22M | $258.29M | (m) | 12 month · $3.11M |
| 2013-02-28 | $0.00 | $3.83M | $96.29M | $-1.39M | $146.85M | $245.58M | $245.70M | (m) | 9 month · $1.87M |
| 2012-11-30 | $0.00 | $3.82M | $94.28M | $-749.00K | $140.20M | $237.55M | $237.71M | (m) | 6 month · $1.50M |
| 2012-08-31 | $0.00 | $3.81M | $92.68M | $-879.00K | $133.41M | $229.01M | $229.22M | (m) | 3 month · $1.03M |
| 2012-05-31 | $0.00 | $3.78M | $89.59M | $-1.23M | $126.69M | $218.84M | $219.05M | (m) | 12 month · $1.83M |
| 2012-02-29 | $0.00 | $3.77M | $86.11M | $-773.00K | $120.58M | $209.68M | $209.98M | (m) | (m) |
| 2011-11-30 | $0.00 | $3.76M | $84.79M | $-1.07M | $115.31M | $202.80M | $203.13M | (m) | (m) |
| 2011-08-31 | $0.00 | $3.74M | $82.93M | $-508.00K | $110.06M | $196.22M | $196.57M | (m) | (m) |
| 2011-05-31 | $0.00 | $3.73M | $81.25M | $-394.00K | $104.06M | $188.65M | $189.10M | (m) | 12 month · $2.99M |
| 2010-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | $153.22M | (m) | 12 month · $709.00K |
| 2009-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | $128.68M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |